In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
US pharma major AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's proprietary VivoVec platform. 5 January 2024
Biotechnology
French rare disease company Innate Pharma has received good news from the US Food and Drug Administration, with a partial clinical hold being lifted from its lacutamab program. 5 January 2024
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma yesterday provided an update on its clinical development programs and outlined its strategic priorities for 2024. 5 January 2024
Biotechnology
Californian rare disease company Ultragenyx Pharmaceutical has received a positive reimbursement decision from the UK’s health technology assessor, the National Institute for Health and Care Excellence (NICE). 5 January 2024
Pharmaceutical
Swiss pharma giant Novartis announced today that it has received approval from the US Food and Drug Administration (FDA) for commercial manufacturing of Pluvicto at new plant. 5 January 2024
Pharmaceutical
Global pharmaceutical giants are lobbying for simultaneous drug launches in India, the USA, and Europe. 5 January 2024
Biotechnology
Boston, USA-based biotech start-up Kojin Therapeutics has announced the appointment of Harvey Berger as its new chairman, president and chief executive (CEO). 5 January 2024
Pharmaceutical
Germany’s Merck KGaA has announced a licensing agreement with New York-based small molecule developer Inspirna. 4 January 2024
Biotechnology
In what was a hectic news day for the German pharm major, Boehringer Ingelheim announced it has entered into a new strategic collaboration and licensing agreement with California, USA-based 3T Biosciences. 4 January 2024
Biotechnology
By Barbara Obstoj-Cardwell. Editor
In full year 2023, the total number of mergers and acquisitions (M&A) in the pharma and biotech sectors was 105, compared with 109 in 2022 and just 92 in 2021, according to tracking by The Pharma Letter (TPL). 4 January 2024
Pharmaceutical
Further extending its reach beyond it core diabetes business, Denmark’s Novo Nordisk today revealed it has entered into separate research collaborations, one with Omega Therapeutics and the other with Cellarity, in the area of cardiometabolic diseases. 4 January 2024
Pharmaceutical
Dublin-headquartered Alkermes has announced new long-term data from a Phase III trial of Lybalvi (olanzapine/samidorphan). 4 January 2024
Biotechnology
Agios Pharmaceuticals’ shares rose 5.2% to $24.02 by close of trading yesterday on the news of positive trial results for its mitapivat. 4 January 2024
Pharmaceutical
China’s Suzhou Ribo Life Science and its Ribocure unit have entered into collaboration with German family-owned pharma major Boehringer Ingelheim to develop novel treatments for non-alcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). 4 January 2024
Pharmaceutical
Not long after the first home-grown GLP-1 agonist was approved in China, the country’s thriving biotech sector looks set to progress another novel candidate in this class with strong potential. 4 January 2024
Biotechnology
A significant collaboration agreement has been reached between Belgian biotech Galapagos and private Californian company BridGene Biosciences. 4 January 2024
Pharmaceutical
US pharma company Esperion Therapeutics on Wednesday announced a $125 million deal with Japanese drugmaker Daiichi Sankyo’s European subsidiary (DSE) to resolve Esperion's demand for $300 million from the company over Esperion's cholesterol reduction drugs. 4 January 2024
Biotechnology
US clinical-stage biotech start-up QurAlis has announced the opening of its European Union (EU) headquarters in Leiden, the Netherlands. 4 January 2024
Biotechnology
French immuno-oncology company Innate Pharma today announced that it has strengthened its leadership and corporate governance with the appointment of two new executive board members. 4 January 2024
Biotechnology
Adding to the growing list pf big pharma licensing and M&A deals in the attractive area of antibody-drug conjugate (ADC) drugs, China-headquartered MediLink Therapeutics has entered into a worldwide collaboration and license accord with Swiss pharma giant Roche. 3 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze